Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized Phase II study were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup